{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:45:19Z","timestamp":1789429519918,"version":"build-2803163510"},"reference-count":45,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Myasthenia Gravis (MG) comprises an autoimmune disorder marked by muscle weakness and fatigue. MG has been associated with comorbid conditions, including dyslipidemia (DL), which may exacerbate the clinical burden of MG and impact the overall quality of life. Materials and Methods: This systematic review and meta-analysis aimed to assess the prevalence of DL in patients with MG. Following PRISMA guidelines, a comprehensive search was conducted in the MEDLINE, Scopus, and Google Scholar databases. Primary outcomes included the pooled prevalence of DL in MG patients, and the relative risk of DL compared to healthy controls. Results: Nineteen studies involving 98,947 MG patients were analyzed. The pooled prevalence of DL was 23.64% (95% CI: 17.01\u201330.98). The relative risk of DL in MG patients versus controls was 1.13 (95% CI: 0.53\u20132.41), indicating no significant increase. Meta-regression revealed a positive correlation between DL prevalence and MG onset age (\u03b2 = 0.02, p &lt; 0.001), with a 2% rise in DL prevalence per 1-year increase in onset age. Regional subgroup analysis showed a statistical trend of higher DL prevalence in the USA (33.02%) compared to Asia (19.89%) and Europe (17.5%). Conclusions: This study found that approximately one in four MG patients has comorbid DL, with MG onset age significantly influencing DL prevalence. These findings highlight the need for personalized management strategies and evaluations (e.g., statins, LP(a) levels). Further research is warranted to elucidate the pathophysiological links between MG and DL.<\/jats:p>","DOI":"10.3390\/medicina61061067","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:53:16Z","timestamp":1749559996000},"page":"1067","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dyslipidemia in Myasthenia Gravis: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6210-2086","authenticated-orcid":false,"given":"Vasileios","family":"Giannopapas","sequence":"first","affiliation":[{"name":"Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2192-9297","authenticated-orcid":false,"given":"Vassiliki","family":"Smyrni","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0052-5678","authenticated-orcid":false,"given":"Georgia","family":"Papagiannopoulou","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Salakou","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0722-9329","authenticated-orcid":false,"given":"Dimitrios K.","family":"Kitsos","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilianna","family":"Bethani","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Zompola","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Tzartos","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-3797","authenticated-orcid":false,"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7443-5179","authenticated-orcid":false,"given":"Sotirios","family":"Giannopoulos","sequence":"additional","affiliation":[{"name":"Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kosmidou","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1196\/annals.1254.053","article-title":"The Epidemiology of Myasthenia Gravis","volume":"998","author":"Phillips","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1212\/CON.0000000000000800","article-title":"Myasthenia Gravis and Congenital Myasthenic Syndromes","volume":"25","author":"Ciafaloni","year":"2019","journal-title":"Contin. Lifelong Learn. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17562864221080520","DOI":"10.1177\/17562864221080520","article-title":"Factors affecting minimal manifestation status induction in myasthenia gravis","volume":"15","author":"Li","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacc.2012.11.002","article-title":"The Worldwide Environment of Cardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy Issues","volume":"60","author":"Laslett","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2217\/imt-2023-0052","article-title":"Role of artesunate in autoimmune diseases and signaling pathways","volume":"15","author":"Gu","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2063103","DOI":"10.1155\/2016\/2063103","article-title":"Serum Oxidized LDL Levels in Type 2 Diabetic Patients with Retinopathy in Mthatha Region of the Eastern Cape Province of South Africa","volume":"2016","author":"Ganjifrockwala","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1874192401105010064","article-title":"Dyslipidaemia in Rheumatological Autoimmune Diseases","volume":"5","author":"Toms","year":"2011","journal-title":"Open Cardiovasc. Med. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1742-2094-8-127","article-title":"Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis","volume":"8","author":"Zivadinov","year":"2011","journal-title":"J. Neuroinflamm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J. Med. Life"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"108602","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ. Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101014","DOI":"10.1016\/j.imr.2023.101014","article-title":"How to understand and report heterogeneity in a meta-analysis: The difference between I-squared and prediction intervals","volume":"12","author":"Borenstein","year":"2023","journal-title":"Integr. Med. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: A practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid.-Based Ment. Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/mus.21074","article-title":"Statins may aggravate myasthenia gravis","volume":"38","author":"Oh","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ejcn.2012.191","article-title":"\u03b2-glucans reduce LDL cholesterol in patients with myasthenia gravis","volume":"67","author":"Andersson","year":"2013","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4103\/neuroindia.NI_804_16","article-title":"Analysis of mortality and related factors in 2195 adult myasthenia gravis patients in a 10-year follow-up study","volume":"65","author":"Liu","year":"2017","journal-title":"Neurol. India"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mus.25625","article-title":"Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis","volume":"56","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_20","first-page":"581","article-title":"Glucose and lipid metabolic disorders in myasthenia gravis patients and its mechanisms","volume":"98","author":"Li","year":"2018","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3889\/oamjms.2018.110","article-title":"Myasthenia Gravis and Associated Diseases","volume":"6","author":"Tanovska","year":"2018","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","article-title":"A study of comorbidities in myasthenia gravis","volume":"120","author":"Misra","year":"2020","journal-title":"Acta Neurol. Belg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/01616412.2021.1948767","article-title":"Risk factors for potential drug\u2013drug interactions in patients with myasthenia gravis","volume":"43","year":"2021","journal-title":"Neurol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e933296","DOI":"10.12659\/MSM.933296","article-title":"Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis","volume":"27","author":"Johnson","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40120-022-00383-3","article-title":"Physician-Reported Perspectives on Myasthenia Gravis in the United States: A Real-World Survey","volume":"11","author":"Mahic","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Phillips, G., Abreu, C., Goyal, A., Li, Y., Whangbo, A., Gelinas, D., Brauer, E., and Bhattacharya, S. (2022). Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults with Generalized Myasthenia Gravis in the United States. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.809999"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Chen, J., Li, Z., Tan, S., Yan, C., Luo, S., Zhou, L., Song, J., Huan, X., and Wang, Y. (2022). Clinical Features of Myasthenia Gravis with Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.879261"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"120480","DOI":"10.1016\/j.jns.2022.120480","article-title":"Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States","volume":"443","author":"Qi","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Digala, L.P., Prasanna, S., Rao, P., Qureshi, A.I., and Govindarajan, R. (2022). Impact of COVID-19 infection among myasthenia gravis patients- a Cerner Real-World DataTM study. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-02564-x"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1007\/s10072-023-06750-8","article-title":"Effects of comorbid diseases on clinical outcomes in patients with myasthenia gravis","volume":"44","author":"Ozdemir","year":"2023","journal-title":"Neurol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40120-024-00619-4","article-title":"Epidemiology, Patient Characteristics, and Treatment Patterns of Myasthenia Gravis in Taiwan: A Population-Based Study","volume":"13","author":"Tsai","year":"2024","journal-title":"Neurol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1007\/s10072-024-07368-0","article-title":"Comorbidity in myasthenia gravis: Multicentric, hospital-based, and controlled study of 178 Italian patients","volume":"45","author":"Iacono","year":"2024","journal-title":"Neurol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"123322","DOI":"10.1016\/j.jns.2024.123322","article-title":"Characteristics and healthcare utilization of patients with myasthenia gravis exacerbation","volume":"468","author":"Qi","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chu, H.T., Tseng, C.C., Liang, C.S., Yeh, T.C., Hu, L.Y., Yang, A.C., Tsai, S.J., and Shen, C.C. (2019). Risk of Depressive Disorders Following Myasthenia Gravis: A Nationwide Population-Based Retrospective Cohort Study. Front. Psychiatry, 10.","DOI":"10.3389\/fpsyt.2019.00481"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ijge.2018.02.010","article-title":"Epidemiology of Dyslipidemia in the Asia Pacific Region","volume":"12","author":"Lin","year":"2018","journal-title":"Int. J. Gerontol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1249\/MSS.0b013e3181c3aa7e","article-title":"Sedentary Behaviors Increase Risk of Cardiovascular Disease Mortality in Men","volume":"42","author":"Warren","year":"2010","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2021.05.007","article-title":"APOE gene variants in primary dyslipidemia","volume":"328","author":"Khalil","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1749-6632.1998.tb10991.x","article-title":"Apolipoprotein in E in Myasthenia Gravis","volume":"841","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/ene.14996","article-title":"The risk of worsening of myasthenia by cardiovascular medication as reflected by reporting frequency","volume":"28","author":"Trillenberg","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/0127722708268538231010041307","article-title":"Antibacterial and Antimalarial Therapeutic Agents: A Patent Perspective","volume":"18","author":"Zhang","year":"2024","journal-title":"Recent. Adv. Inflamm. Allergy Drug Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1752-1947-4-61","article-title":"Statin-associated weakness in myasthenia gravis: A case report","volume":"4","author":"Keogh","year":"2010","journal-title":"J. Med. Case Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jocn.2013.11.009","article-title":"Statins can induce myasthenia gravis","volume":"21","author":"Gale","year":"2014","journal-title":"J. Clin. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Yan, J., Yang, S., Han, L., Ba, X., Shen, P., Lin, W., Li, T., Zhang, R., Huang, Y., and Huang, Y. (2023). Dyslipidemia in rheumatoid arthritis: The possible mechanisms. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1254753"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s10067-023-06539-2","article-title":"Dyslipidemia is associated with inflammation and organ involvement in systemic lupus erythematosus","volume":"42","author":"Huang","year":"2023","journal-title":"Clin. Rheumatol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/6\/1067\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:49:37Z","timestamp":1760032177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/6\/1067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["medicina61061067"],"URL":"https:\/\/doi.org\/10.3390\/medicina61061067","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}